Clinic
Banner - University Medical Center Phoenix
Banner - University Medical Center Phoenix was paid $140.85M by Medicaid between Jan 2018 and Dec 2024, across 574 billing codes. Its largest line is 99285, emergency room visit (most serious) — 21% of everything it billed.
33Billing provider infoBANNER - UNIVERSITY MEDICAL CENTER PHOENIX
PHOENIX, AZ 85006
PHOENIX, AZ 85006
33aNPI1841224870assigned 07/10/2006
33bProvider typeSleep Disorder Diagnostic Clinic/Center
28Total paid$140.85M
24GClaims3,763,687
24DCodes billed574
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Sleep Disorder Diagnostic Clinic/Center providers in Arizona
Rank by total paid#2 of 18
Median peer was paid$166K
This provider vs. median848×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 498,688 | $18.13M | |
| 2019 | 465,898 | $19.21M | |
| 2020 | 411,930 | $17.59M | |
| 2021 | 585,546 | $20.91M | |
| 2022 | 629,258 | $22.65M | |
| 2023 | 639,469 | $24.24M | |
| 2024incomplete | 532,898 | $18.12M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 21% | 69,213 | 61,742 | $29.62M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 79,423 | 72,433 | $20.47M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 10% | 21,314 | 19,872 | $14.53M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.8% | 46,105 | 43,253 | $11.00M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.7% | 8,597 | 7,918 | $3.87M |
| 58571 | 2.2% | 742 | 626 | $3.08M | |
| 47562 | 1.9% | 711 | 658 | $2.62M | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 23,587 | 21,515 | $2.45M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 1.6% | 2,487 | 2,162 | $2.28M |
| G0378 | Hospital observation service, per hour | 1.6% | 64,568 | 30,954 | $2.19M |
| 49083 | 1.4% | 6,987 | 2,892 | $2.03M | |
| L8699 | Prosthetic implant, not otherwise specified | 1.4% | 796 | 687 | $1.94M |
562 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 40,529 | $1.69M |
| 58661 | 1.2% | 551 | $1.64M | |
| C1889 | Implantable/insertable device, not otherwise classified | 1.1% | 663 | $1.60M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.1% | 1,361 | $1.55M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.1% | 8,845 | $1.50M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.0% | 4,263 | $1.47M |
| 80053 | Comprehensive metabolic panel | 1.0% | 157,151 | $1.43M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 12,981 | $1.39M |
| G0277 | Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval | <1% | 4,661 | $1.33M |
| 74174 | <1% | 2,749 | $1.27M | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 8,328 | $1.23M |
| 70496 | <1% | 2,784 | $1.11M | |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 3,642 | $1.09M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,985 | $1.07M |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 12,784 | $973K |
| 43235 | <1% | 2,310 | $905K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,322 | $854K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 1,898 | $786K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 8,273 | $760K |
| 58662 | <1% | 513 | $720K | |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 95 | $675K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 2,064 | $639K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,860 | $624K |
| 11043 | <1% | 1,951 | $580K | |
| 11045 | <1% | 1,709 | $553K | |
| 70487 | <1% | 1,266 | $553K | |
| 93458 | <1% | 537 | $541K | |
| 70491 | <1% | 1,508 | $527K | |
| 95811 | <1% | 944 | $487K | |
| 93970 | <1% | 2,570 | $439K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,509 | $403K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 3,604 | $396K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 19,717 | $375K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 616 | $374K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 4,270 | $370K |
| 72131 | <1% | 1,090 | $365K | |
| 74183 | <1% | 847 | $356K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,453 | $349K |
| 93505 | <1% | 142 | $349K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 4,390 | $329K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 345 | $321K |
| 36224 | <1% | 60 | $309K | |
| 36430 | <1% | 2,401 | $293K | |
| 93798 | <1% | 5,030 | $293K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 432 | $271K |
| C1776 | Joint device (implantable) | <1% | 159 | $260K |
| C9600 | Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch | <1% | 57 | $255K |
| 71250 | <1% | 2,777 | $249K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 2,653 | $246K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 22,125 | $243K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 7,487 | $238K |
| 70486 | <1% | 4,056 | $233K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 16,104 | $231K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 8,170 | $227K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 81,578 | $217K |
| J0897 | Injection, denosumab, 1 mg | <1% | 238 | $193K |
| 74170 | <1% | 1,147 | $186K | |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | <1% | 130 | $175K |
| C1874 | Stent, coated/covered, with delivery system | <1% | 325 | $173K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 20,011 | $173K |
| C1767 | Generator, neurostimulator (implantable), non-rechargeable | <1% | 15 | $168K |
| 93971 | <1% | 4,792 | $166K | |
| 88185 | <1% | 192 | $152K | |
| 59200 | <1% | 783 | $150K | |
| 86920 | <1% | 3,508 | $141K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 2,468 | $140K |
| C1769 | Guide wire | <1% | 7,833 | $138K |
| 91010 | <1% | 438 | $137K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 66,823 | $135K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,843 | $133K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,913 | $131K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 21,966 | $129K |
| 99205 | Prolong outpt/office vis | <1% | 1,442 | $129K |
| 70498 | <1% | 3,144 | $127K | |
| 72146 | <1% | 346 | $121K | |
| 88341 | <1% | 2,849 | $118K | |
| 94621 | <1% | 553 | $114K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,600 | $112K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 135 | $110K |
| 29581 | <1% | 11,681 | $108K | |
| 93975 | <1% | 1,108 | $105K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 3,423 | $100K |
| 10060 | <1% | 1,419 | $98K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 12,005 | $97K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 7,539 | $96K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,396 | $94K |
| 77334 | <1% | 133 | $94K | |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | <1% | 41 | $93K |
| 75574 | <1% | 980 | $89K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 81 | $87K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 372 | $87K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 703 | $85K |
| 71045 | Radiologic examination, chest; single view | <1% | 54,453 | $79K |
| 11046 | <1% | 219 | $78K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 4,114 | $78K |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 461 | $66K |
| 50200 | <1% | 131 | $61K | |
| 72141 | <1% | 1,214 | $57K | |
| 80320 | <1% | 17,970 | $57K | |
| 93976 | <1% | 8,127 | $55K | |
| 58558 | <1% | 55 | $54K | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 90 | $54K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,344 | $51K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,231 | $50K |
| 44970 | <1% | 12 | $50K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,332 | $48K |
| 93451 | <1% | 30 | $44K | |
| 74018 | <1% | 2,929 | $44K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 436 | $41K |
| 86923 | <1% | 3,341 | $40K | |
| C1781 | Mesh (implantable) | <1% | 494 | $38K |
| 75561 | <1% | 172 | $38K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 67,533 | $36K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 6,828 | $36K |
| 76642 | <1% | 686 | $34K | |
| Q9956 | Injection, octafluoropropane microspheres, per ml | <1% | 225 | $34K |
| 76942 | <1% | 1,284 | $33K | |
| 77336 | <1% | 674 | $32K | |
| 20680 | <1% | 15 | $32K | |
| 58670 | <1% | 12 | $31K | |
| 70355 | <1% | 4,694 | $31K | |
| J3240 | Injection, thyrotropin alpha, 0.9 mg, provided in 1.1 mg vial | <1% | 33 | $29K |
| J3490 | Unclassified drugs | <1% | 141,672 | $26K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 18,553 | $26K |
| 88348 | <1% | 50 | $25K | |
| 95800 | <1% | 266 | $25K | |
| 73700 | <1% | 271 | $24K | |
| 43264 | <1% | 57 | $24K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,123 | $23K |
| 77066 | Tomosynthesis, mammo | <1% | 371 | $23K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,940 | $22K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 6,241 | $22K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 430 | $22K |
| 74178 | <1% | 77 | $22K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 33,173 | $22K |
| 97162 | <1% | 151 | $22K | |
| Q4186 | Epifix, per square centimeter (add-on, list separately in addition to primary procedure) | <1% | 22 | $22K |
| 96376 | <1% | 29,732 | $20K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 672 | $19K |
| 76536 | <1% | 363 | $18K | |
| 83880 | <1% | 13,616 | $18K | |
| 77012 | <1% | 34 | $18K | |
| 73630 | <1% | 4,717 | $17K | |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | <1% | 38 | $16K |
| 15275 | <1% | 186 | $16K | |
| 36591 | <1% | 3,292 | $15K | |
| 95806 | <1% | 155 | $15K | |
| 77386 | <1% | 150 | $14K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 48,335 | $14K |
| 74246 | <1% | 71 | $14K | |
| 73562 | <1% | 6,206 | $14K | |
| C1729 | Catheter, drainage | <1% | 4,151 | $14K |
| 73130 | <1% | 4,295 | $14K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,195 | $14K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 62,466 | $13K |
| 72156 | <1% | 51 | $13K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 59 | $12K |
| 72193 | <1% | 26 | $12K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 13,076 | $12K |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 53 | $12K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 12 | $12K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 2,762 | $11K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 6,259 | $11K |
| 72157 | <1% | 12 | $11K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 167,221 | $10K |
| 77080 | <1% | 320 | $10K | |
| 12002 | <1% | 962 | $10K | |
| 73030 | <1% | 5,140 | $10K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 192 | $10K |
| 72100 | <1% | 2,361 | $9K | |
| 96367 | <1% | 6,361 | $9K | |
| 73701 | <1% | 26 | $9K | |
| 74230 | <1% | 89 | $9K | |
| 73610 | <1% | 3,714 | $9K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 16,762 | $8K |
| 93017 | <1% | 1,581 | $8K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 11,254 | $8K |
| 93312 | <1% | 49 | $8K | |
| 99201 | <1% | 127 | $8K | |
| 12001 | <1% | 1,159 | $8K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 44,973 | $8K |
| 10061 | <1% | 14 | $7K | |
| 12011 | <1% | 386 | $7K | |
| 81025 | <1% | 33,060 | $7K | |
| 72128 | <1% | 282 | $7K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 61 | $6K |
| 59025 | Fetal non-stress test | <1% | 250 | $6K |
| 76801 | <1% | 5,622 | $6K | |
| 76770 | <1% | 871 | $6K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,952 | $6K |
| 29445 | <1% | 107 | $6K | |
| 73502 | <1% | 2,377 | $5K | |
| 72197 | <1% | 25 | $5K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,896 | $5K |
| 87631 | <1% | 1,894 | $5K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 223 | $5K |
| 80329 | <1% | 1,645 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 24,309 | $4K |
| 84484 | <1% | 52,213 | $4K | |
| 84702 | <1% | 15,673 | $4K | |
| 87116 | <1% | 1,774 | $4K | |
| 97161 | <1% | 10,204 | $4K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 863 | $4K |
| 77065 | Tomosynthesis, mammo | <1% | 343 | $4K |
| 76830 | Ultrasound, transvaginal | <1% | 3,687 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,840 | $4K |
| 83690 | <1% | 41,072 | $3K | |
| 41800 | <1% | 33 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12,890 | $3K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 18 | $3K |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 1,543 | $3K |
| 82803 | <1% | 6,285 | $3K | |
| 73080 | <1% | 1,429 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,352 | $3K |
| 86850 | <1% | 17,292 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,865 | $3K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 23,007 | $3K |
| 73110 | <1% | 2,522 | $2K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 237 | $2K |
| 87040 | <1% | 21,069 | $2K | |
| 71101 | <1% | 1,169 | $2K | |
| 82728 | <1% | 4,713 | $2K | |
| 73090 | <1% | 2,232 | $2K | |
| 97597 | <1% | 51 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 10,757 | $2K |
| 96417 | <1% | 2,076 | $2K | |
| 81001 | <1% | 48,636 | $2K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 500 | $2K |
| 97165 | <1% | 5,485 | $2K | |
| 73590 | <1% | 3,130 | $2K | |
| 82947 | <1% | 92,943 | $2K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 139,663 | $2K |
| 15271 | <1% | 97 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 31,976 | $2K |
| 72158 | <1% | 13 | $2K | |
| 73120 | <1% | 638 | $2K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 853 | $2K |
| 92611 | <1% | 88 | $2K | |
| C9733 | Non-ophthalmic fluorescent vascular angiography | <1% | 42 | $2K |
| 76376 | <1% | 2,110 | $1K | |
| 83605 | <1% | 32,058 | $1K | |
| 73552 | <1% | 1,185 | $1K | |
| 17250 | <1% | 33 | $1K | |
| 76377 | <1% | 4,829 | $1K | |
| 88342 | <1% | 3,960 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 45,255 | $1K |
| 95819 | <1% | 40 | $1K | |
| 82565 | <1% | 21,832 | $1K | |
| 96411 | <1% | 30 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 10,074 | $1K |
| 76870 | <1% | 850 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 37,404 | $1K |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 11,581 | $1K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,549 | $1K |
| 85610 | <1% | 45,945 | $1K | |
| 74181 | <1% | 13 | $1K | |
| 90715 | <1% | 5,871 | $1K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 831 | $1K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 2,977 | $1K |
| 36247 | <1% | 31 | $991.69 | |
| 83735 | <1% | 41,871 | $930.06 | |
| 88313 | <1% | 2,479 | $926.28 | |
| 85027 | <1% | 41,699 | $912.73 | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 1,759 | $827.50 |
| 72040 | <1% | 608 | $821.85 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 6,556 | $816.57 |
| 99152 | <1% | 5,559 | $802.76 | |
| 86870 | <1% | 196 | $735.86 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,997 | $726.14 |
| A9270 | Non-covered item or service | <1% | 168,960 | $712.90 |
| 87070 | <1% | 9,951 | $712.66 | |
| 85055 | <1% | 8,284 | $696.11 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 34,214 | $695.34 |
| 87075 | <1% | 5,382 | $672.28 | |
| 87088 | <1% | 18,558 | $665.05 | |
| 72170 | <1% | 1,317 | $661.37 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,118 | $653.41 |
| 81003 | <1% | 20,851 | $652.97 | |
| 85730 | <1% | 16,607 | $639.77 | |
| 80051 | <1% | 3,435 | $605.27 | |
| 86635 | <1% | 1,438 | $580.30 | |
| 73560 | <1% | 747 | $555.51 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,427 | $538.33 |
| 73060 | <1% | 909 | $525.64 | |
| 73620 | <1% | 386 | $522.12 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 41,978 | $520.72 |
| 84703 | <1% | 11,928 | $505.76 | |
| 97116 | <1% | 9,055 | $502.60 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 5,641 | $464.80 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 516 | $461.99 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 24,225 | $456.16 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 23 | $455.86 |
| 88307 | <1% | 4,456 | $434.17 | |
| 85379 | <1% | 5,568 | $419.32 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 18,362 | $395.88 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 2,684 | $387.34 |
| 82550 | <1% | 12,569 | $376.01 | |
| 86901 | <1% | 19,850 | $374.74 | |
| 0042T | <1% | 545 | $371.66 | |
| 73140 | <1% | 192 | $365.61 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 4,527 | $362.54 |
| 84145 | <1% | 3,153 | $360.38 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 101 | $355.38 |
| 85384 | <1% | 1,607 | $340.80 | |
| 94664 | <1% | 738 | $320.91 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,078 | $316.44 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 6,043 | $310.90 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,184 | $310.06 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 10,355 | $294.85 |
| 87186 | <1% | 7,665 | $284.60 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 13,540 | $275.25 |
| 86828 | <1% | 128 | $274.89 | |
| 87210 | <1% | 5,440 | $272.84 | |
| 86140 | <1% | 11,042 | $271.48 | |
| 73600 | <1% | 634 | $266.15 | |
| 82378 | <1% | 693 | $261.48 | |
| 82330 | <1% | 5,699 | $243.50 | |
| 15853 | <1% | 75 | $229.03 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 14,786 | $228.85 |
| J1815 | Injection, insulin, per 5 units | <1% | 19,148 | $222.84 |
| 72072 | <1% | 12 | $219.84 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,966 | $208.50 |
| 80061 | Lipid panel | <1% | 2,610 | $200.85 |
| 86900 | <1% | 17,907 | $199.44 | |
| 84100 | <1% | 15,772 | $197.66 | |
| 84550 | <1% | 2,745 | $186.62 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 3,814 | $178.53 |
| 87077 | <1% | 9,322 | $177.00 | |
| 85014 | <1% | 8,367 | $174.74 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 6,595 | $148.82 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,959 | $132.85 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 1,281 | $130.76 |
| A9578 | Injection, gadobenate dimeglumine (multihance multipack), per ml | <1% | 3,436 | $129.08 |
| 20610 | <1% | 30 | $126.43 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 5,650 | $125.17 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 856 | $124.59 |
| 82607 | <1% | 1,869 | $122.25 | |
| 85018 | <1% | 8,992 | $120.40 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 3,253 | $118.45 |
| 77001 | <1% | 116 | $113.15 | |
| 87205 | <1% | 10,365 | $109.79 | |
| 88304 | <1% | 2,505 | $103.47 | |
| 72192 | <1% | 13 | $99.92 | |
| 82784 | <1% | 1,398 | $95.21 | |
| 84439 | <1% | 3,986 | $94.55 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 24,807 | $91.33 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 9,628 | $91.05 |
| 89051 | <1% | 7,772 | $87.42 | |
| 87206 | <1% | 2,545 | $87.18 | |
| 92610 | <1% | 44 | $86.80 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 6,342 | $86.05 |
| 87102 | <1% | 2,071 | $85.72 | |
| 83615 | <1% | 4,037 | $85.43 | |
| 96368 | <1% | 3,085 | $81.50 | |
| 76937 | <1% | 1,482 | $80.92 | |
| 82010 | <1% | 3,416 | $80.44 | |
| 82746 | <1% | 1,183 | $77.95 | |
| 87081 | <1% | 1,051 | $76.43 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 5,094 | $75.54 |
| 93041 | <1% | 2,862 | $71.54 | |
| 84132 | <1% | 6,475 | $70.66 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 4,668 | $69.02 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 5,261 | $66.52 |
| 85652 | <1% | 5,522 | $65.81 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 2,819 | $65.36 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 6,538 | $62.46 |
| 84466 | <1% | 2,452 | $60.20 | |
| 73100 | <1% | 391 | $59.66 | |
| 73070 | <1% | 450 | $59.62 | |
| 86803 | <1% | 492 | $59.44 | |
| 84520 | <1% | 5,797 | $55.25 | |
| 94760 | <1% | 3,975 | $54.84 | |
| 96523 | <1% | 38 | $53.46 | |
| A9581 | Injection, gadoxetate disodium, 1 ml | <1% | 296 | $52.32 |
| 95957 | <1% | 101 | $50.80 | |
| 87497 | <1% | 45 | $43.58 | |
| 86769 | <1% | 385 | $42.75 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 703 | $39.52 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 4,854 | $38.49 |
| 80197 | <1% | 2,011 | $35.42 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 3,153 | $33.13 |
| 87015 | <1% | 769 | $32.39 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,732 | $31.66 |
| 85460 | <1% | 725 | $30.68 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,637 | $28.50 |
| J7999 | Compounded drug, not otherwise classified | <1% | 2,646 | $28.32 |
| 88112 | <1% | 1,266 | $27.27 | |
| 36410 | <1% | 19 | $26.88 | |
| 90686 | <1% | 1,064 | $23.09 | |
| 82945 | <1% | 1,251 | $22.70 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 5,836 | $21.81 |
| 74328 | <1% | 142 | $21.49 | |
| 83540 | <1% | 2,531 | $20.55 | |
| 84157 | <1% | 2,385 | $19.75 | |
| 87340 | <1% | 1,439 | $19.26 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 4,849 | $18.86 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 347 | $18.39 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,295 | $18.03 |
| 84156 | <1% | 2,983 | $17.98 | |
| 93356 | <1% | 855 | $17.60 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 951 | $17.56 |
| 85046 | <1% | 3,760 | $16.75 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,657 | $16.74 |
| 84460 | <1% | 2,074 | $16.57 | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,001 | $16.24 |
| 82310 | <1% | 339 | $15.11 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 2,955 | $14.13 |
| 82042 | <1% | 1,027 | $12.53 | |
| 86592 | <1% | 872 | $12.32 | |
| 84450 | <1% | 1,746 | $12.28 | |
| 80305 | <1% | 13 | $11.97 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,037 | $11.46 |
| 87807 | <1% | 34 | $8.57 | |
| 85007 | <1% | 1,222 | $8.45 | |
| 84295 | <1% | 1,840 | $6.71 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 4,015 | $6.70 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 937 | $6.16 |
| 87147 | <1% | 1,173 | $5.74 | |
| 84300 | <1% | 262 | $5.23 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 615 | $3.49 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 808 | $1.71 |
| 80076 | <1% | 748 | $1.56 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 2,048 | $0.45 |
| 85347 | 0% | 1,888 | $0.00 | |
| 82140 | 0% | 1,894 | $0.00 | |
| 51702 | 0% | 173 | $0.00 | |
| 36600 | 0% | 117 | $0.00 | |
| 82731 | 0% | 100 | $0.00 | |
| Q0114 | Fern test | 0% | 471 | $0.00 |
| J1453 | Injection, fosaprepitant, 1 mg | 0% | 664 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 1,410 | $0.00 |
| 88302 | 0% | 896 | $0.00 | |
| 96416 | 0% | 407 | $0.00 | |
| J0640 | Injection, leucovorin calcium, per 50 mg | 0% | 451 | $0.00 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | 0% | 29 | $0.00 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 944 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 1,497 | $0.00 |
| 87324 | 0% | 69 | $0.00 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 2,176 | $0.00 |
| 80164 | 0% | 296 | $0.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 36 | $0.00 |
| 87076 | 0% | 17 | $0.00 | |
| 86922 | 0% | 172 | $0.00 | |
| 93325 | 0% | 105 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 94 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 388 | $0.00 |
| J3489 | Injection, zoledronic acid, 1 mg | 0% | 103 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 289 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 672 | $0.00 |
| 84165 | 0% | 64 | $0.00 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 25 | $0.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 3,366 | $0.00 |
| 88173 | 0% | 142 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 40 | $0.00 |
| 88312 | 0% | 206 | $0.00 | |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | 0% | 53 | $0.00 |
| 84112 | 0% | 14 | $0.00 | |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | 0% | 192 | $0.00 |
| 86334 | 0% | 142 | $0.00 | |
| 82570 | 0% | 522 | $0.00 | |
| 88346 | 0% | 114 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 346 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 90 | $0.00 |
| 84155 | 0% | 32 | $0.00 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 147 | $0.00 |
| 80202 | 0% | 179 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 293 | $0.00 |
| 80074 | 0% | 39 | $0.00 | |
| J7517 | Mycophenolate mofetil, oral, 250 mg | 0% | 37 | $0.00 |
| 83970 | 0% | 72 | $0.00 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 52 | $0.00 |
| C2625 | Stent, non-coronary, temporary, with delivery system | 0% | 25 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 322 | $0.00 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 67 | $0.00 |
| 87045 | 0% | 36 | $0.00 | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 64 | $0.00 |
| 78018 | 0% | 40 | $0.00 | |
| 71270 | 0% | 18 | $0.00 | |
| 93321 | 0% | 12 | $0.00 | |
| 92950 | 0% | 20 | $0.00 | |
| 85041 | 0% | 18 | $0.00 | |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 0% | 18 | $0.00 |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | 0% | 32 | $0.00 |
| 90714 | 0% | 14 | $0.00 | |
| 92978 | 0% | 12 | $0.00 | |
| 72070 | 0% | 16 | $0.00 | |
| 82553 | 0% | 51 | $0.00 | |
| 80177 | 0% | 550 | $0.00 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 309 | $0.00 |
| 87449 | 0% | 444 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 2,102 | $0.00 |
| 83021 | 0% | 52 | $0.00 | |
| 96415 | 0% | 3,046 | $0.00 | |
| 88184 | 0% | 192 | $0.00 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 169 | $0.00 |
| 77300 | 0% | 127 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 1,575 | $0.00 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 171 | $0.00 |
| 86706 | 0% | 407 | $0.00 | |
| J0456 | Injection, azithromycin, 500 mg | 0% | 1,262 | $0.00 |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 0% | 39 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 42 | $0.00 |
| 87176 | 0% | 385 | $0.00 | |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | 0% | 1,153 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 0% | 415 | $0.00 |
| 82105 | 0% | 388 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 369 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 1,204 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 455 | $0.00 |
| 74021 | 0% | 98 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 353 | $0.00 |
| 90732 | 0% | 28 | $0.00 | |
| 88311 | 0% | 266 | $0.00 | |
| J0613 | Injection, calcium gluconate (wg critical care), not therapeutically equivalent to j0612, 10 mg | 0% | 81 | $0.00 |
| 86704 | 0% | 199 | $0.00 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 100 | $0.00 |
| 82040 | 0% | 30 | $0.00 | |
| 83010 | 0% | 44 | $0.00 | |
| J1836 | Injection, metronidazole, 10 mg | 0% | 412 | $0.00 |
| J2599 | Injection, vasopressin (american regent), not therapeutically equivalent to j2598, 1 unit | 0% | 53 | $0.00 |
| 83521 | 0% | 116 | $0.00 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 848 | $0.00 |
| 94762 | 0% | 41 | $0.00 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 42 | $0.00 |
| 84134 | 0% | 73 | $0.00 | |
| Q0247 | Injection, sotrovimab, 500 mg | 0% | 135 | $0.00 |
| G0009 | Administration of pneumococcal vaccine | 0% | 28 | $0.00 |
| 88331 | 0% | 78 | $0.00 | |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | 0% | 79 | $0.00 |
| 86780 | 0% | 173 | $0.00 | |
| J7507 | Tacrolimus, immediate release, oral, 1 mg | 0% | 83 | $0.00 |
| 88350 | 0% | 159 | $0.00 | |
| J3590 | Unclassified biologics | 0% | 18 | $0.00 |
| 83883 | 0% | 246 | $0.00 | |
| 72020 | 0% | 17 | $0.00 | |
| C1759 | Catheter, intracardiac echocardiography | 0% | 29 | $0.00 |
| 83930 | 0% | 31 | $0.00 | |
| 83935 | 0% | 30 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 597 | $0.00 |
| 74420 | 0% | 12 | $0.00 | |
| 97166 | 0% | 20 | $0.00 | |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 35 | $0.00 |
| 97010 | 0% | 698 | $0.00 | |
| C1730 | Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes) | 0% | 62 | $0.00 |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 35 | $0.00 |
| Q0222 | Injection, bebtelovimab, 175 mg | 0% | 60 | $0.00 |
| 87184 | 0% | 47 | $0.00 | |
| A9540 | Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries | 0% | 13 | $0.00 |
| 86320 | 0% | 59 | $0.00 | |
| J9045 | Injection, carboplatin, 50 mg | 0% | 35 | $0.00 |
| J0611 | Injection, calcium gluconate (wg critical care), per 10 ml | 0% | 20 | $0.00 |
| Q9964 | High osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml | 0% | 15 | $0.00 |
| C1732 | Catheter, electrophysiology, diagnostic/ablation, 3d or vector mapping | 0% | 25 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 17 | $0.00 |
| J1805 | Injection, esmolol hydrochloride, 10 mg | 0% | 105 | $0.00 |
| C1753 | Catheter, intravascular ultrasound | 0% | 13 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 18 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 18 | $0.00 |
| 82525 | 0% | 12 | $0.00 | |
| J3535 | Drug administered through a metered dose inhaler | 0% | 12 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 15 | $0.00 |
| 82150 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPOST, DAN (CEO)
Parent organizationBANNER HEALTH
| Provider | Location | Paid |
|---|---|---|
| Banner - University Medical Center Tucson Campus LLC | Tucson, AZ | $194.42M |
| Banner - University Medical Center South Campus LLC | Tucson, AZ | $82.41M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.